Table 2.
Neuromuscular Disease Characteristics and Treatment in our Patient Population.
| Variable | n (%) | n (%) reporting CAM use |
|---|---|---|
| Diagnosis | ||
| Duchenne muscular dystrophy | 19 (36.5) | 4 (21.1) |
| Non-Duchenne muscular dystrophy | 8 (15.4) | 0 (0) |
| Spinal muscular atrophy | 7 (13.5) | 2 (28.6) |
| Charcot-Marie-Tooth | 7 (13.5) | 2 (28.6) |
| Myopathy | 5 (9.6) | 1 (20.0) |
| Other | 6 (11.5) | 1 (16.7) |
| Years since diagnosis | ||
| 0-4 | 17 (33.3) | 3 (17.7) |
| 5-9 | 13 (25.9) | 3 (23.1) |
| 10-14 | 15 (29.4) | 3 (20.0) |
| 15+ | 6 (11.8) | 1 (16.7) |
| Ambulatory status | ||
| Walks >200 m | 20 (39.2) | 4 (20.0) |
| Walks ≤200 m or nonambulatory | 31 (60.8) | 6 (19.4) |
| Wheelchair use | ||
| Yes | 19 (82.6) | 3 (15.8) |
| No | 4 (17.4) | 1 (25.0) |
| Noninvasive positive pressure ventilation device use | ||
| Yes | 12 (23.5) | 5 (41.7) |
| No | 39 (76.5) | 5 (12.8) |
| Steroid use | ||
| Yes | 15 (30.2) | 4 (26.7) |
| No | 37 (69.8) | 6 (16.2) |